Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Brief Summary: The primary study objective is to demonstrate the superiority of APF530 500 mg given subcutaneously (SC) compared with ondansetron 0.15 mg/kg given intravenously (IV) (up to a maximum of 16 mg) in the delayed-phase (\> 24-120 hours) complete response (CR) rate (defined as no emesis and no use of rescue medications) in subjects receiving highly emetogenic chemotherapy (HEC) as defined by the 2011 ASCO CINV guidelines


Options:
A: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone, Drug: palonosetron hydrochloride, Drug: prochlorperazine, Drug: placebo | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: dexamethasone, Drug: granisetron hydrochloride, Drug: prochlorperazine, Drug: placebo | Arm Label: Arm III; Type: ACTIVE_COMPARATOR; Interventions: Drug: aprepitant, Drug: dexamethasone, Drug: palonosetron hydrochloride, Drug: placebo | Arm Label: Arm IV; Type: EXPERIMENTAL; Interventions: Drug: dexamethasone, Drug: palonosetron hydrochloride, Drug: prochlorperazine, Drug: placebo | Intervention Type: DRUG; Name: aprepitant; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): Arm I, Arm II, Arm III, Arm IV | Intervention Type: DRUG; Name: granisetron hydrochloride; Assigned to Arm(s): Arm II | Intervention Type: DRUG; Name: palonosetron hydrochloride; Assigned to Arm(s): Arm I, Arm III, Arm IV | Intervention Type: DRUG; Name: prochlorperazine; Assigned to Arm(s): Arm I, Arm II, Arm IV | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm I, Arm II, Arm III, Arm IV
B: Arm Label: APF530 500 mg SC; Type: EXPERIMENTAL; Interventions: Drug: APF530, Drug: Ondansetron placebo, Drug: Fosaprepitant, Drug: Dexamethasone | Arm Label: ondansetron 0.15 mg/kg IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ondansetron, Drug: APF530 placebo, Drug: Fosaprepitant, Drug: Dexamethasone | Intervention Type: DRUG; Name: APF530; Assigned to Arm(s): APF530 500 mg SC | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): ondansetron 0.15 mg/kg IV | Intervention Type: DRUG; Name: Ondansetron placebo; Assigned to Arm(s): APF530 500 mg SC | Intervention Type: DRUG; Name: APF530 placebo; Assigned to Arm(s): ondansetron 0.15 mg/kg IV | Intervention Type: DRUG; Name: Fosaprepitant; Assigned to Arm(s): APF530 500 mg SC, ondansetron 0.15 mg/kg IV | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): APF530 500 mg SC, ondansetron 0.15 mg/kg IV
C: Intervention Type: DRUG; Name: MK0869, aprepitant / Duration of Treatment: 3 days; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: ondansetron / Duration of Treatment: 4 days; Assigned to Arm(s): N/A
D: Arm Label: Placebo + Granisetron + Dexamethasone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Granisetron, Drug: Dexamethasone, Drug: Placebo | Arm Label: Rolapitant; Type: EXPERIMENTAL; Interventions: Drug: Rolapitant, Drug: Granisetron, Drug: Dexamethasone | Intervention Type: DRUG; Name: Rolapitant; Assigned to Arm(s): Rolapitant | Intervention Type: DRUG; Name: Granisetron; Assigned to Arm(s): Placebo + Granisetron + Dexamethasone, Rolapitant | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Placebo + Granisetron + Dexamethasone, Rolapitant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Granisetron + Dexamethasone

Answer: B